Bluebird Bio Inc (BLUE) 34.24 $BLUE
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
bluebird bio Appoints Mark Vachon to its Board of Directors
Business Wire - Wed Jul 16, 3:05PM CDT
bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company's board of directors.
Grading Sobek's Mid-Year Biotech Stock Predictions
at The Street - Wed Jul 09, 9:14AM CDT
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
bluebird bio Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Jul 08, 5:58PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $34.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 450,000 shares of common stock.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why bluebird bio Inc. Stock Faltered
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of bluebird bio , a clinical-stage...
bluebird bio Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jul 07, 3:02PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company
Business Wire - Mon Jun 30, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition of Precision Genome Engineering, Inc., or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington. Pregenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications.
This Week in Biotech: A Double-Dose of Hot Potato
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 21, 11:32AM CDT
With the SPDR S&P Biotech Index up 52% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jun 21, 8:00AM CDT
June has proven to be a pretty decent month so far for the overall markets. For three health-care stocks, the third week of the month wasn't just decent. Gains of over 25% in a matter of days probably qualify as great. One of this week's big...
Biotech Stock Mailbag: Zafgen, Bluebird, MannKind
at The Street - Fri Jun 20, 7:03AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Bluebird (BLUE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:43AM CDT
Bluebird (BLUE) Enters Overbought Territory
Clinical Studies, Review Extensions, Appointments, and Conference Schedules - Analyst Notes on Karyopharm, Orexigen, INSYS, bluebird bio and AMAG Pharmaceuticals
PR Newswire - Wed Jun 18, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Orexigen Therapeutics, Inc. (NASDAQ: OREX), INSYS Therapeutics, Inc. (NASDAQ: INSY), bluebird bio, Inc. (NASDAQ: BLUE) and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3825-100free.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
bluebird bio Appoints Mark Vachon to its Board of Directors
Business Wire - Wed Jul 16, 3:05PM CDT
bluebird bio (Nasdaq: BLUE), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Mark Vachon has joined the company's board of directors.
Grading Sobek's Mid-Year Biotech Stock Predictions
at The Street - Wed Jul 09, 9:14AM CDT
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
bluebird bio Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Jul 08, 5:58PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $34.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 450,000 shares of common stock.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why bluebird bio Inc. Stock Faltered
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of bluebird bio , a clinical-stage...
bluebird bio Announces Proposed Public Offering of Common Stock
Business Wire - Mon Jul 07, 3:02PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company
Business Wire - Mon Jun 30, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the acquisition of Precision Genome Engineering, Inc., or Pregenen, a privately held biotechnology company headquartered in Seattle, Washington. Pregenen is a leader in the development of gene editing and cell signaling technologies with a broad range of potential therapeutic applications.
This Week in Biotech: A Double-Dose of Hot Potato
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 21, 11:32AM CDT
With the SPDR S&P Biotech Index up 52% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jun 21, 8:00AM CDT
June has proven to be a pretty decent month so far for the overall markets. For three health-care stocks, the third week of the month wasn't just decent. Gains of over 25% in a matter of days probably qualify as great. One of this week's big...
Biotech Stock Mailbag: Zafgen, Bluebird, MannKind
at The Street - Fri Jun 20, 7:03AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Bluebird (BLUE) Enters Overbought Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:43AM CDT
Bluebird (BLUE) Enters Overbought Territory
Clinical Studies, Review Extensions, Appointments, and Conference Schedules - Analyst Notes on Karyopharm, Orexigen, INSYS, bluebird bio and AMAG Pharmaceuticals
PR Newswire - Wed Jun 18, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Orexigen Therapeutics, Inc. (NASDAQ: OREX), INSYS Therapeutics, Inc. (NASDAQ: INSY), bluebird bio, Inc. (NASDAQ: BLUE) and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3825-100free.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
